Kinetics of nigral degeneration in a chronic model of MPTP-treated mice

Neuroscience Letters

Volumn 234, Issue 1, 1997, Pages 47-50

  Bezard, Erwan ^a   Dovero, Sandra ^a   Bioulac, Bernard ^a   Gross, Christian E ^a  

^a Basal Gang   (France)

Author keywords

1 Methyl 4 phenyl 1,2,3,6 tetrahydropyridine; Chronic model; Mice; Parkinson's disease; Slow evolution of disease; Tyrosine hydroxylase

Indexed keywords

ANIMAL MODEL; ARTICLE; BRAIN PROTECTION; MOUSE; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SUBSTANTIA NIGRA;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANALYSIS OF VARIANCE; ANIMALS; CELL DEATH; CHRONIC DISEASE; DISEASE MODELS, ANIMAL; KINETICS; MALE; MICE; NERVE DEGENERATION; NEUROTOXINS; SUBSTANTIA NIGRA; TYROSINE 3-MONOOXYGENASE;

EID: 0030770812     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3940(97)00663-0     Document Type: Article

References (26)

1. Agid Y. Parkinson's disease: pathophysiology, Lancet. 337:1991;1321-1323.
2. Benazzouz A., Gross C., Bioulac B. MPTP-induced hemiparkinsonism in monkeys: behavioral, mechanographic, electromyographic and immunohistochemical studies. Exp. Brain Res. 90:1992;116-120.
3. Bezard E., Boraud T., Bioulac B., Gross C. Compensatory effects of glutamatergic inputs to the substantia nigra pars compacta in experimental parkinsonism. Neuroscience. 81:1997;399-404.
4. Bezard E., Boraud T., Bioulac B., Gross C.E. Presymptomatic revelation of experimental parkinsonism. NeuroReport. 8:1997;435-438.
5. Bezard, E., Dovero, S., Bioulac, B. and Gross, C., Effect of different schedules of MPTP administration on dopaminergic neurodegeneration in mice, Exp. Neurol., (1997) in press.
6. Bezard, E., Imbert, C., Deloire, X., Bioulac, B. and Gross, C., A chronic MPTP model reproducing the slow evolution of Parkinson's disease: evolution of motor symptoms in monkey, Brain Res., (1997) in press.
7. Braak H., Braak E., Yilmazer D., Vos R.A.I.D., Jansen E.N.H., Bohl J. Pattern of brain destruction in Parkinson's and Alzheimer diseases. J. Neural Transm. 103:1996;455-490.
8. Burns R.S., Chiueh C.C., Markey S.P., Ebert M.H., Jacobowitz D.J., Kopin I.J. A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc. Natl. Acad. Sci. USA. 80:1983;4546-4550.
9. Date I., Felten S.Y., Felten D.L. The nigrostriatal dopaminergic system in MPTP-treated mice shows more prominent recovery by syngeneic adrenal medullary graft than by allogeneic or xenogeneic graft. Brain Res. 545:1991;191-198.
10. Ehringer H., Hornykiewicz O. Verteilung von Noradrenalin und Dopamin (3-Hydroxytyramin) im Gehirn des Menschen und ihr Verhalten bei Erkrankungen des extrapyramidalen Systems. Klin. Wochenschr. 38:1960;1236-1239.
11. Gerlach M., Riederer P. Animal models of Parkinson's disease: an empirical comparison with the phenomenology of the disease in man. J. Neural Transm. 103:1996;987-1041.
12. Gerlach M., Riederer P., Przuntek H., Youdim M.B.H. MPTP mechanisms of neurotoxicity and their implications for Parkinson's disease. Eur. J. Pharmacol. 208:1991;273-286.
13. German D.C., Nelson E.L., Liang C.-L., Speciale S.G., Sinton C.M., Sonsalla P.K. The neurotoxin MPTP causes degeneration of specific nucleus A8, A9, and A10 dopaminergic neurons in the mouse. Neurodegeneration. 5:1996;299-312.
14. Hassler R. Zur Pathologie der Paralysis agitans und des postenzephalitischen Parkinsonismus. J. Psychol. Neurol. 48:1938;387-476.
15. Heikkila R.E., Sonsalla P. The MPTP-treated mouse as a model of parkinsonism: how good is it? Neurochem. Int. 20:1991;299-303.
16. Heikkila R.E., Steber B.A., Manzino L., Sonsalla P.K. Some features of the nigrostriatal neurotoxin MPTP in the mouse. Mol. Chem. Neuropathol. 10:1989;171-183.
17. Hirsch E.C., Mouatt A., Thomasset M., Javoy-Agid F., Agid Y., Graybiel A.M. Expression of calbindin D28K-like immunoreactivity in catecholaminergic cell groups of the human midbrain: normal distribution and distribution in Parkinson's disease. Neurodegeneration. 1:1992;83-93.
18. Jackson-Lewis V., Jakowec M., Burke R.E., Przedborski S. Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neurodegeneration. 4:1995;257-269.
19. Langston J.W., Forno L.S., Rebert C.S., Irwin I. Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl 1-1,2,3,6, tetrahydropyridine (MPTP) in the squirrel monkey. Brain Res. 292:1984;390-394.
20. Nelson E.L., Liang C.L., Sinton C.M., German D.C. Midbrain dopaminergic neurons in the mouse: computer-assisted mapping. J. Comp. Neurol. 369:1996;361-371.
21. Poewe, W., The preclinical phase of Parkinson's disease. In D.B. Calne (Ed.), Advances in Research on Neurodegeneration, Birkhäuser, Boston, MA, 1993, pp. 43-53.
22. Riachi N.J., Harik S.I. Strain differences in systemic MPTP neurotoxicity in mice correlate best with monoamine oxidase activity at the blood-brain barrier. Life Sci. 42:1988;2359-2363.
23. Scherman D., Desnos C., Darchen F., Pollack P., Javoy-Agid F., Agid Y. Striatal dopamine deficiency in Parkinson's disease: role of aging. Ann. Neurol. 26:1989;551-557.
24. Schultz W., Studer A., Jonsson G., Sundstrüm E., Mefford I. Deficits in behavioral initiation and execution processes in monkeys with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism. Neurosci. Lett. 59:1985;225-232.
25. Schulzer M., Lee C.S., Mak E.K., Vingerhoets F.J.G., Calne D.B. A mathematical model of pathogenesis in idiopathic parkinsonism. Brain. 117:1994;509-516.
26. Yamada T., McGeer P.L., Baimbridge K.G., McGeer E.G. Relative sparing in Parkinson's disease of substantia nigra dopamine neurons containing calbindin-D28K. Brain Res. 526:1990;303-337.